As Western sanctions strain Iran’s economy, the pharmaceutical and tech sectors are pivoting towards self-sufficiency, particularly in healthcare. Zist Takhmir, a leading pharmaceutical company, is making significant progress in producing essential medications, including cancer treatments, while adhering to strict safety protocols. Operating from Tehran’s Pardis Technology Park, Zist Takhmir is also increasing probiotic production. The park fosters local manufacturing of medical equipment, fulfilling 85% of new hospital needs and producing around 10,000 medical beds annually. Despite the complexities of nuclear negotiations, Iran’s focus on domestic production aims to bolster healthcare resilience amid external pressures.